Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Improving the activity of BH3 mimetic venetoclax: a case study

Andrew Wei • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia Leukemia Cytarabine Venetoclax

Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses clinical trials investigating the effect of BH3 mimetic drugs, such as venetoclax, on acute myeloid leukemia (AML). Current studies are trying to improve the activity of venetoclax in combination with low-dose chemotherapy and hypomethylating agents in patients with poor risk FLT3, DNMT3A or IDH mutations to produce a longer, more sustainable remission. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrew Wei

New approaches to target TP53-mutated AML: the ADAPT trial
10:05
New approaches to target TP53-mutated AML: the ADAPT trial
Andrew Wei • 20 Sep 2026
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
18:47
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
Andrew Wei et al. • 20 Sep 2026
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Wei et al. • 19 Sep 2025
Current challenges in clinical genomics
Current challenges in clinical genomics
Andrew Wei et al. • 29 Sep 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals